The CEO of Californian company Nektar Therapeutics says that 2007
has been key in transforming the company into a fully integrated
drug development organisation, despite the setback with Pfizer's
inhaled insulin product Exubera.
We've all cringed at stories of people dumping their partners via
text message but in the world of business, Pfizer seems to have
taken things to a new level when its Exubera partners were
allegedly left to find out the product...
Biopharmaceutical firm Nektar has agreed to fork out $25m (€20m) to
settle a patent lawsuit by the University of Alabama in Huntsville
(UAH) concerning the company's PEGylation delivery technology
currently used in eight approved...
Its upcoming inhalable insulin drug may prove a blockbuster but
Nektar's 2005 results brought the biopharmaceutical company further
in the red, with a net loss of $108.2m (€91m) in Q4 more than five
times higher than the $19.3m...